Amarin Corp Plc (AMRN)

[ziploc_1]

I would like more transparency from Amarin re material facts , which influence the company's future...e.g.

In June of 2018...QUOTE..."Amarin Corporation (NASDAQ:AMRN) has entered into a multi-faceted collaboration with Mochida Pharmaceutical Co.
Under the agreement, Amarin obtained an exclusive license to certain Mochida intellectual property to focus on the development and commercialization of early-stage drug products and indications based on the omega-3 acid, EPA (eicosapentaenoic acid).
FINANCIAL TERMS ARE NOT DISCLOSED."....

This agreement was signed before the release of the R-IT study findings and Amarin took a chance to pay $2 million to Mochida, up front, at a difficult time for company when they were facing a lot of unknowns.

In the case of MND-2119, which may well be a drug Amarin eventually used to replace Vascepa, we remained uninformed about whether Amarin will need to pay royalties to Mochida for its use, or, if they do, at what percent of the sales revenues.